Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Gilead Sciences Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Accounts payable	808)	582)	737)	833)	903)	537)	622)	550)	586)	622)	627)	905)	614)	565)	583)	705)	585)	608)	570)	844)	527)	532)	590)
Accrued rebates	4,931)	4,215)	4,185)	3,892)	4,113)	3,923)	4,263)	3,802)	3,714)	3,494)	3,477)	3,479)	3,674)	3,519)	3,450)	3,244)	3,368)	3,290)	3,369)	3,460)	3,343)	3,337)	3,457)
Current portion of long-term debt, net	2,806)	2,806)	2,806)	1,815)	1,812)	1,810)	3,667)	1,798)	1,793)	4,037)	2,283)	2,273)	2,270)	1,021)	1,025)	1,516)	2,511)	2,261)	2,259)	2,757)	1,498)	2,999)	1,999)
Other current liabilities	3,753)	3,586)	4,616)	5,464)	4,897)	4,511)	4,463)	5,130)	5,852)	5,811)	4,141)	4,580)	3,865)	4,115)	3,500)	6,145)	3,781)	4,055)	3,507)	4,336)	4,141)	3,696)	2,833)
Current liabilities	12,298)	11,189)	12,344)	12,004)	11,725)	10,781)	13,015)	11,280)	11,945)	13,964)	10,528)	11,237)	10,423)	9,220)	8,558)	11,610)	10,245)	10,214)	9,705)	11,397)	9,509)	10,564)	8,879)
Long-term debt, net, excluding current portion	22,135)	22,140)	22,146)	24,896)	21,437)	21,540)	21,527)	23,189)	23,189)	21,209)	22,956)	22,957)	22,953)	25,195)	25,183)	25,179)	25,175)	27,914)	27,907)	28,645)	27,792)	21,103)	22,098)
Long-term income taxes payable	866)	859)	819)	830)	782)	738)	1,967)	2,039)	2,088)	2,610)	3,775)	3,916)	3,982)	3,888)	4,793)	4,767)	4,642)	4,596)	5,022)	5,016)	5,020)	5,107)	5,595)
Deferred tax liability	597)	652)	709)	724)	794)	907)	933)	1,588)	1,984)	2,106)	2,401)	2,673)	3,036)	3,364)	3,687)	4,356)	4,603)	4,374)	4,464)	3,914)	—)	—)	—)
Other long-term obligations	1,181)	1,291)	1,338)	1,295)	1,397)	1,416)	1,395)	1,280)	925)	1,354)	1,277)	1,179)	1,106)	988)	944)	976)	962)	1,176)	1,430)	1,214)	1,086)	1,018)	990)
Long-term liabilities	24,779)	24,942)	25,012)	27,745)	24,410)	24,601)	25,822)	28,096)	28,186)	27,279)	30,409)	30,725)	31,077)	33,435)	34,607)	35,278)	35,382)	38,060)	38,823)	38,789)	33,898)	27,228)	28,683)
Total liabilities	37,077)	36,131)	37,356)	39,749)	36,135)	35,382)	38,837)	39,376)	40,131)	41,243)	40,937)	41,962)	41,500)	42,655)	43,165)	46,888)	45,627)	48,274)	48,528)	50,186)	43,407)	37,792)	37,562)
Preferred stock, par value $0.001 per share; none outstanding	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, par value $0.001 per share	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)	1)
Additional paid-in capital	8,678)	8,367)	8,138)	7,700)	7,327)	7,022)	6,813)	6,500)	6,279)	6,008)	5,793)	5,550)	5,226)	5,031)	4,867)	4,661)	4,492)	4,271)	4,092)	3,880)	3,712)	3,511)	3,311)
Accumulated other comprehensive income (loss)	36)	(18)	92)	132)	73)	93)	69)	28)	32)	10)	(20)	2)	98)	87)	73)	83)	74)	39)	38)	(60)	23)	70)	46)
Retained earnings	12,825)	11,324)	10,931)	11,497)	11,074)	11,165)	10,656)	16,304)	16,002)	15,139)	15,223)	15,687)	15,756)	15,117)	14,986)	16,324)	16,903)	15,392)	14,821)	14,381)	13,709)	14,445)	18,709)
Total Gilead stockholders’ equity	21,540)	19,674)	19,162)	19,330)	18,475)	18,281)	17,539)	22,833)	22,314)	21,158)	20,997)	21,240)	21,081)	20,236)	19,927)	21,069)	21,470)	19,703)	18,952)	18,202)	17,445)	18,027)	22,067)
Noncontrolling interest	(84)	(84)	(84)	(84)	(85)	(84)	(84)	(84)	(72)	(64)	(58)	(31)	(24)	(21)	(12)	(5)	1)	7)	12)	19)	26)	115)	112)
Total stockholders’ equity	21,456)	19,590)	19,078)	19,246)	18,390)	18,197)	17,455)	22,749)	22,242)	21,094)	20,939)	21,209)	21,057)	20,215)	19,915)	21,064)	21,471)	19,710)	18,964)	18,221)	17,471)	18,142)	22,179)
Total liabilities and stockholders’ equity	58,533)	55,721)	56,434)	58,995)	54,525)	53,579)	56,292)	62,125)	62,373)	62,337)	61,876)	63,171)	62,557)	62,870)	63,080)	67,952)	67,098)	67,984)	67,492)	68,407)	60,878)	55,934)	59,741)

Accounts payable: The accounts payable balance fluctuated within a range, cresting at 905 million in December 2021 before trending downward to 582 million by September 2025. Overall, the level shows some volatility but no clear long-term upward or downward trend.
Accrued rebates: This liability increased steadily over the observed periods, starting from 3457 million and rising to 4931 million by September 2025. This trend suggests growing rebate obligations, potentially reflecting higher sales volumes or changes in rebate agreements.
Current portion of long-term debt, net: The current portion of long-term debt exhibited significant variation, peaking at 4037 million in June 2023 then decreasing to 2806 million toward the end of the timeline. This indicates shifting repayment schedules or refinancing activities.
Other current liabilities: Other current liabilities experienced notable volatility, with spikes such as 6145 million at the end of 2021 and 5811 million in June 2023. Despite fluctuations, the balance remains elevated, typically exceeding 3500 million.
Current liabilities: Current liabilities varied broadly, with peaks such as 13964 million in June 2023 and lows near 8558 million in March 2022. The overall pattern suggests short-term obligations are subject to periodic increases, possibly linked to operational cycles or financing strategies.
Long-term debt, net, excluding current portion: Long-term debt showed a declining tendency from 22098 million in March 2020 to a low near 21435 million during multiple quarters in 2024, with a notable increase back to 24896 million in March 2025 before stabilizing near 22135 million. This reflects active debt management through repayments and borrowings.
Long-term income taxes payable: This liability decreased significantly from 5595 million in March 2020 to 819 million in June 2025, indicating either settlement of tax obligations or reductions in deferred tax liabilities over time.
Deferred tax liability: Deferred tax liability, not reported until late 2020, steadily decreased from 3914 million to 597 million by September 2025. This suggests recognition of deferred taxes over time or changes in tax positions reducing future tax obligations.
Other long-term obligations: Other long-term obligations fluctuated moderately between approximately 900 million and 1400 million, without a strong directional trend, indicating relatively stable miscellaneous long-term liabilities.
Long-term liabilities: Long-term liabilities declined from a high of 38823 million in early 2021 to around 24410 million in mid-2024 but experienced an increase again to near 27745 million by March 2025, showing variability possibly driven by changes in debt and tax liabilities.
Total liabilities: Total liabilities peaked at over 50186 million in December 2020 and subsequently exhibited a downward trend to around 35382 million by mid-2024, before rising again to about 39749 million in early 2025. This pattern reflects active management of obligations including debt and other liabilities.
Common stock: The par value of common stock remained constant at 1 million throughout the periods, reflecting no changes in share capital structure.
Additional paid-in capital: Additional paid-in capital steadily increased from 3311 million in March 2020 to 8678 million by September 2025, indicating ongoing equity injections or the impact of share-based compensation plans.
Accumulated other comprehensive income (loss): Accumulated other comprehensive income (loss) showed volatility, with values ranging from -60 million in late 2020 to peaks of over 130 million in early 2025. The fluctuating values indicate changes in unrealized gains/losses on assets or liabilities recorded in equity.
Retained earnings: Retained earnings demonstrated irregular movements, initially declining from 18709 million to 13709 million in late 2020, then increasing again to near 16304 million in late 2021 before decreasing sharply to approximately 10656 million in early 2024. After this low point, there was gradual recovery, reaching 12825 million in September 2025. This reflects variability in profitability and dividend policies.
Total stockholders’ equity: Total stockholders’ equity fluctuated, declining from 22179 million in early 2020 to about 17455 million in early 2024, then recovering to around 21456 million by September 2025. This trajectory suggests resilience in equity position despite periods of pressure on earnings and retained earnings.
Noncontrolling interest: Noncontrolling interest decreased from 112 million to -84 million, remaining negative from 2021 onward, indicating possibly losses attributable to minority interests or adjustments reducing these interests in the group.
Total liabilities and stockholders’ equity: The combined total demonstrated a peak near 68407 million in late 2020, followed by a general decline to about 53579 million in mid-2024, and a subsequent rebound to 58533 million by September 2025. This trend aligns with fluctuations in both liabilities and equity components throughout the periods.

Download chart

Gilead Sciences Inc. (NASDAQ:GILD)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data